Botanix Pharmaceuticals Ltd has released a press release.
Botanix Update on BTX 1801 Clinical Development
Filed with ASX ·
Watch Botanix Pharmaceuticals' latest callBotanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call · Replay · Mar 2Read the transcript of Botanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Botanix Pharmaceuticals Limited on 6ix
In the deck
Earlier from Botanix Pharmaceuticals
- BTX 1702 Rosacea Study Approval
- Botanix receives A$6.87m R&D Tax Incentive Refund
- Phase 2a Study Shows BTX 1801 Eradicates S. Aureus
- Antimicrobial Data Published in Peer-Reviewed Journal
- Update on BTX 1801 Phase 2a Clinical Study
Later from Botanix Pharmaceuticals
- New Canine Pilot Study Supports Further AD Investigation
- Final Report and Annual Report to Shareholders
- Canine Atopic Dermatitis Program Launched
- Notification regarding unquoted securities - BOT
- FDA Qualified Infectious Disease Product Status for BTX 1801
Follow Botanix Pharmaceuticals into a list and get an email when it puts out news.
Follow Botanix Pharmaceuticals